CMAC (Continuous Manufacturing and Advanced Crystallisation)
Established in 2011, CMAC is a world-class international hub for manufacturing research and training. Working in partnership with industry, our purpose is to transform current manufacturing processes into the medicine supply chain of the future.
CMAC has been established through close collaboration with industry and the support of its partners, which include GlaxoSmithKline, AstraZeneca, Novartis, Bayer, Roche, Lilly, Takeda & Pfizer.
The CMAC National Facility offers contract research support through the delivery of services within crystallisation (batch & continuous), process development, formulation, product/process analysis and advanced materials characterisation. In particular, applying our expertise in crystallisation, PAT and high end analytical services.